CCI imposes Rs 10 lakh fine on Goa's chemist association
The Competition Commission of India found that CDAG was indulging in anti-competitive practices by controlling the supply chain through which drugs and medicines are supplied
BS B2B Bureau B2B Connect | New Delhi
“In a subsequent complaint filed by Xcel Healthcare, it was brought to the notice of the Commission that CDAG was restraining pharmaceutical companies such as Glenmark Pharmaceuticals Limited and Wockhardt Limited from doing business with non-authorised stockists and thereby not complying with the order of the Commission. The Commission took suo-moto cognisance and ordered the Director General to investigate the matter,” said a CCI press release.
Following detailed investigation, the commission found that CDAG was indulging in anti-competitive practices in complete disregard to CCI order dated June 11, 2012. It was found that CDAG was continuing to exercise control on the supply chain through which drugs and medicines are made available in the market through the practice of requirement of LOC/NOC prior to appointment of stockists by pharmaceutical companies without having any legal or statutory authority in this respect.
Also Read
“Observing that the case involved continued contravention and utmost disrespect to the Commission’s earlier order, CCI imposed a penalty calculated at the rate of 10% of the average receipts of CDAG amounting to Rs 10.62 lakhs. The penalty is to be deposited within 60 days of receipt of the order,” added the release.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Oct 28 2014 | 3:31 PM IST